Alendronate sodium


CAS No. : 121268-17-5

Alendronate sodium,121268-17-5
Product Details
Cat No:A000595
Synonyms:G-704650, MK-217; 121268-17-5; Alendronate monosodium trihydrate; Alendronate sodium hydrate; ALENDRONATE SODIUM; Alendronate sodium trihydrate
Molecular Formula:C₄H₁₂NaNO₇P₂ · 3 H₂O
Molecular Weight:325.12
Target:Farnesyl Diphosphate Synthase
Price:Get quote
We would like to match the lowest price on market if possible.

Your information is safe with us.

refresh
Appearance:white solid powder
Purity:98%
Cat No:A000595
Cas No:121268-17-5
Product-Name:Alendronate sodium
MDL No:MFCD01748233
InChI:InChI=1S/C4H13NO7P2.Na.3H2O/c5-3-1-2-4(6,13(7,8)9)14(10,11)12;;;;/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12);;3*1H2/q;+1;;;/p-1
InChIKey:DCSBSVSZJRSITC-UHFFFAOYSA-M
SMILES:C(CC(O)(P(=O)(O)O)P(=O)(O)[O-])CN.O.O.O.[Na+]
Alendronate sodium is the sodium salt of alendronate, a second generation bisphosphonate and synthetic analog of pyrophosphate with bone anti-resorption activity. Alendronate sodium binds to and inhibits the activity of geranyltranstransferase (farnesyl pyrophosphate synthetase), an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which is important in the process of osteoclast turnover. As a result, osteoclast activity is inhibited and bone resorption and turnover are reduced. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
1: Goh TL, Kendrick-Jones J. Alendronate sodium-induced interstitial nephritis. Intern Med J. 2017 Nov;47(11):1326-1327. doi: 10.1111/imj.13608. PubMed PMID: 29105273.
2: de Arruda JA, Silva P, Amaral MB, Cotta F, Avendanho R, Mesquita R. Erythema multiforme induced by alendronate sodium in a geriatric patient: A case report and review of the literature. J Clin Exp Dent. 2017 Jul 1;9(7):e929-e933. doi: 10.4317/jced.53653. eCollection 2017 Jul. PubMed PMID: 28828163; PubMed Central PMCID: PMC5549594.
3: Zhang Y, Chen X, Tang Y, Lu Y, Guo L, Zhong D. Bioequivalence of generic alendronate sodium tablets (70 mg) to Fosamax(®) tablets (70 mg) in fasting, healthy volunteers: a randomized, open-label, three-way, reference-replicated crossover study. Drug Des Devel Ther. 2017 Jul 11;11:2109-2119. doi: 10.2147/DDDT.S138286. eCollection 2017. PubMed PMID: 28744102; PubMed Central PMCID: PMC5513855.
4: Franzoni JS, Soares FMP, Zaniboni E, Vedovello Filho M, Santamaria MP, Dos Santos GMT, Esquisatto MAM, Felonato M, Mendonca FAS, Franzini CM, Santamaria M Jr. Zoledronic acid and alendronate sodium and the implications in orthodontic movement. Orthod Craniofac Res. 2017 Aug;20(3):164-169. doi: 10.1111/ocr.12192. Epub 2017 Jun 27. PubMed PMID: 28653350.
5: Liu Y, Shi F, Bo L, Zhi W, Weng J, Qu S. A novel alginate-encapsulated system to study biological response to critical-sized wear particles of UHMWPE loaded with alendronate sodium. Mater Sci Eng C Mater Biol Appl. 2017 Oct 1;79:679-686. doi: 10.1016/j.msec.2017.05.119. Epub 2017 May 17. PubMed PMID: 28629068.
6: Elitez Y, Ekinci M, Ilem-Ozdemir D, Gundogdu E, Asikoglu M. Tc-99m Radiolabeled Alendronate Sodium Microemulsion: Characterization and Permeability Studies across Caco-2 Cells. Curr Drug Deliv. 2017 Jun 12. doi: 10.2174/1567201814666170613082752. [Epub ahead of print] PubMed PMID: 28606033.
7: Kunisaki C, Tanaka Y, Kosaka T, Miyamoto H, Sato S, Suematsu H, Yukawa N, Sato K, Izumisawa Y, Akiyama H, Taguri M, Yamanaka T, Endo I. A Comparative Study of Intravenous Injection Form and Oral Jelly Form of Alendronate Sodium Hydrate for Bone Mineral Disorder after Gastrectomy. Digestion. 2017;95(2):162-171. doi: 10.1159/000458755. Epub 2017 Feb 18. PubMed PMID: 28214864.
8: Liu Y, Shi F, Gong K, Liu Y, Zhi W, Weng J, Qu S. Study on critical-sized ultra-high molecular weight polyethylene wear particles loaded with alendronate sodium: in vitro release and cell response. J Mater Sci Mater Med. 2017 Apr;28(4):56. doi: 10.1007/s10856-017-5865-z. Epub 2017 Feb 16. PubMed PMID: 28210968.
9: Bone HG, Walter MA, Hurley ME, Epstein S. Pharmacokinetics of coadministration of levothyroxine sodium and alendronate sodium new effervescent formulation. Osteoporos Int. 2017 May;28(5):1745-1752. doi: 10.1007/s00198-017-3941-3. Epub 2017 Feb 16. PubMed PMID: 28204953; PubMed Central PMCID: PMC5393287.
10: Camati PR, Giovanini AF, de Miranda Peixoto HE, Schuanka CM, Giacomel MC, de Araújo MR, Zielak JC, Scariot R, Deliberador TM. Immunoexpression of IGF1, IGF2, and osteopontin in craniofacial bone repair associated with autogenous grafting in rat models treated with alendronate sodium. Clin Oral Investig. 2017 Jun;21(5):1895-1903. doi: 10.1007/s00784-016-1975-0. Epub 2016 Oct 22. PubMed PMID: 27771828.
Recommended Products
  • CAS No. :129655-38-5
    Product Name:

    5-(ethoxycarbonyl)-1H-indole-2-carboxylic acid

    Cat No: M128807 View details
  • CAS No. :121314-69-0
    Product Name:

    R-2,2/'-dihydroxy-[1,1/'-Binaphthalene]-3,3/'-dicarboxaldehyde

    Cat No: M128808 View details
  • CAS No. :199273-62-6
    Product Name:

    2-Pyridinamine,N,N,6-trimethyl-(9CI)

    Cat No: M128809 View details
  • CAS No. :110371-27-2
    Product Name:

    bicyclo[3.2.1]octane-1,5-dicarboxylic acid MonoMethyl ester

    Cat No: M128811 View details